EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN'S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

Marc Ferrante  1     Xiaomei Liao  2     Yinuo Pang  2     Valerie Pivorunas  2     Tadakazu Hisamatsu  3    
1 University Hospitals Leuven,Leuven,Belgium
2 AbbVie,North Chicago,United States
3 Kyorin University School of Medicine,Tokyo,Japan

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing